Cardiorenal metabolic syndrome and diabetic cognopathy

CardioRenal Medicine

Volumn 3, Issue 4, 2013, Pages 265-282

  Hayden, M R ^a,b,c   Banks, W A ^e   Shah, G N ^f   Gu, Z ^b   Sowers, J R ^a,b,c,d  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Diabetes and Cardiovascular Research Lab   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Blood brain barrier; Diabetic cognopathy; Neurovascular unit; Remodeling; Type 2 diabetes mellitus; Ultrastructure

Indexed keywords

AMYLIN; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; CHOLINESTERASE INHIBITOR; INSULIN RECEPTOR; MINERALOCORTICOID RECEPTOR; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE;

ADAPTIVE IMMUNITY; ALZHEIMER DISEASE; ARTICLE; ATTENTION; BLOOD BRAIN BARRIER; BRAIN DISEASE; CARDIORENAL METABOLIC SYNDROME; CARDIORENAL SYNDROME; CHRONIC KIDNEY DISEASE; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DEPRESSION; DEPTH PERCEPTION; DIABETES MELLITUS; DIABETIC COGNOPATHY; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; EPISODIC MEMORY; EXECUTIVE FUNCTION; EXERCISE; HUMAN; HYPERAMYLASEMIA; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INTELLIGENCE; LEARNING; LEARNING DISORDER; LINGUISTICS; METABOLIC SYNDROME X; MITOCHONDRION; MOTOR PERFORMANCE; MULTIINFARCT DEMENTIA; NEUROFIBRILLARY TANGLE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROBLEM SOLVING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SEMANTIC MEMORY; SENILE PLAQUE; SMOKING; VISION; WEIGHT REDUCTION; WHITE MATTER; AGING; ASTROCYTE; CELL JUNCTION; DEMENTIA; DIABETIC PATIENT; DYSGLYCEMIA; IMMUNE RESPONSE; LIFESTYLE; MICROGLIA; NERVE DEGENERATION; OVERNUTRITION; PERICYTE; PRIORITY JOURNAL; TIGHT JUNCTION;

EID: 84896719323     PISSN: 16643828     EISSN: 16645502     Source Type: Journal    
DOI: 10.1159/000357113     Document Type: Article

References (64)

1. Sowers JR, Whaley-Connell A, Hayden MR: The role of overweight and obesity in the cardiorenal syndrome. Cardiorenal Med 2011; 1: 5-13.
2. Kodl CT, Seaquist ER: Cognitive dysfunction and diabetes mellitus. Endocr Rev 2008; 29: 494-511. (Pubitemid 351831510)
3. Gregg EW, Narayan KM: T2DM and cognitive function: are cognitive impairment and dementia complications of type 2 diabetes? Clin Geriatr 2000; 8: 57-82.
4. Hayden MR, Tyagi SC, Kerklo MM, Nicolls MR: Type 2 diabetes mellitus as a conformational disease. JOP 2005; 6: 287-302. (Pubitemid 41581749)
5. Bomboi G, Castello L, Consentino F, Glubilel F, Orzi F, Volpe M: Alzheimer's disease and endothelial dysfunction. Neurol Sci 2010; 31: 1-8.
6. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P: Risk of dementia in diabetes mellitus: a systemic review. Lancet Neurol 2006; 5: 64-74. (Pubitemid 41790697)
7. Ott A, Stolk RP, van Harskamp F, et al: Diabetes mellitus and risk of dementia: the Rotterdam study. Neurology 1999; 53: 1037-1942.
8. Cukierman T, Gerstein HC, Williamson JD: Cognitive decline and dementia in diabetes -systematic overview of prospective observational studies. Diabetologia 2005; 48: 2460-2469. (Pubitemid 41738208)
9. Jacobson AM, Musen G, Ryan CM, et al: Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 2007; 356: 1842-1852. (Pubitemid 46698465)
10. McCrimmon RJ, Ryan, CM, Frier BM: Diabetes and cognitive dysfunction. Lancet 2012; 379: 2291-2299.
11. Lin CH, Sheu WH: Hypoglycemic episodes and risk of dementia in diabetes mellitus: 7-year follow-up study. J Intern Med 2013; 273: 102-110.
12. Hayden MR, Karuparthi PR, Manrique CM, Lastra G, Habibi J, Sowers JR: Longitudinal ultrastructure study of islet amyloid in the HIP rat model of type 2 diabetes mellitus. Exp Biol Med (Maywood) 2007; 232: 772-779. (Pubitemid 46827819)
13. Craft S: The role of metabolic disorders in Alzheimer's disease and vascular dementia: two roads converged. Arch Neurol 2009: 66: 300-305.
14. Banks WA, Kastin AJ: Differential permeability of the blood-brain barrier to two pancreatic peptides: insulin and amylin. Peptides 1998; 19: 883-889. (Pubitemid 28312286)
15. Trevaskis JL, Coffey T, Cole R, et al: Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms. Endocrinology 2008; 149: 5679-5687.
16. Jackson K, Barisone GA, Diaz E, Jin LW, Decarli C, Despa F: Amylin deposition in the brain: a second amyloid in Alzheimer's disease? Ann Neurol 2013, E-pub ahead of print. 17 Luchsinger JA, Gustafson DR: Adiposity, type 2 diabetes, and Alzheimer's disease. J Alzheimers Dis 2009; 16: 693-704.
17. Banks WA: Role of the blood-brain barrier in the evolution of feeding and cognition. Ann NY Acad Sci 2012; 1264: 13-19.
18. Bell RD, Zlokovic BV: Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease Acta Neuropathol 2009; 118: 103-113.
19. Hawkins BT, Davis TP: The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005; 57: 173-185. (Pubitemid 41043883)
20. Abbott JN, Ronnback L, Hansson E: Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006; 7: 41-53. (Pubitemid 41828930)
21. Cui J, Chen S, Zhang C, et al: Inhibition of MMP-9 by a selective gelatinase inhibitor protects neurovasculature from embolic focal cerebral ischemia. Mol Neurodegener 2012; 7: 21.
22. Armulik A, Genove G, Mae M, et al: Pericytes regulate the blood-brain barrier. Nature 2010; 468: 557-561.
23. Daneman R, Zhou L, Kebede AA, Barres BA: Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature 2010; 468: 562-566.
24. Bell RD, Winkler EA, Sagare AP, Singh I, LaRue B, Deane R, Zlokovic BV: Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 2010; 68: 409-427.
25. Shah GN, Price TO, Banks WA, et al: Pharmacological inhibition of mitochondrial carbonic anhydrases protects mouse cerebral pericytes from high glucose-induced oxidative stress and apoptosis. J Pharmacol Exp Ther 2013; 344: 637-645.
26. Price TO, Eranki V, Banks WA, Ercal N, Shah GN: Toprimate treatment protects blood-brain barrier pericytes from hyperglycemia-induced oxidative damage in diabetic mice. Endocrinology 2012; 153: 362-372.
27. Lange S, Trost A, Tempfer H, et al: Brain pericyte plasticity as a potential drug target in CNS repair. Drug Discov Today 2013; 18: 456-463.
28. Hayden MR, Yang Y, Habibi J, Bagree SV, Sowers JR: Pericytopathy: oxidative stress and impaired cellular longevity in the pancreas and skeletal muscle in metabolic syndrome and type 2 diabetes. Oxid Med Cell Longev 2010; 3: 290-303.
29. Paul G, Ozen I, Christophersen NS, et al: The adult human brain harbors multipotent perivascular mesenchymal stem cells. PLoS One 2012; 7:e35577.
30. Sofroniew V, Vinters HV: Astrocytes: biology and pathology. Acta Neurpathol 2010; 119: 7-35.
31. Coleman ES, Dennis JC, Braden TD, Judd RL, Posner P: Insulin treatment prevents diabetes-induced alterations in astrocyte glutamate uptake and GFAP content in rats at 4 and 8 weeks of diabetes duration. Brain Res 2010; 1306: 131-141.
32. Koehler RC, Roman RJ, Harder DR: Astrocytes and the regulation of cerebral blood flow. Trends Neurosci 2009; 32: 160-169.
33. Novak V, Zhao P, Manor B, et al: Adhesion molecules, altered vasoreactivity, and brain atrophy in type 2 diabetes. Diabetes Care 2011; 34: 2438-2441.
34. Graham NL, Emery T, Hodges JR: Distinctive cognitive profiles in Alzheimer's disease and subcortical vascular dementia. J Neurol Neurosurg Psychiatry 2004; 75: 61-67.
35. Bowler JV, Eliasziw M, Steenhuis R, et al: Comparative evolution of Alzheimer's disease, vascular dementia, and mixed dementia. Arch Neurol 1997; 54: 697-703. (Pubitemid 27255592)
36. Mathias JL, Burke J: Cognitive functioning in Alzheimer's and vascular dementia: a meta-analysis. Neuropsychology 2009; 23: 411-423.
37. Strachan MW, Reynolds RM, Frier BM, Mitchell RJ, Price JF: The relationship between type 2 diabetes and dementia. Br Med Bull 2008; 88: 131-146.
38. Manrique C, DeMarco VG, Aroor AR, et al: Obesity and insulin resistance induce early development of diastolic dysfunction in young female mice fed a Western diet. Endocrinology 2013; 154: 3632-3642.
39. McKinley MJ, Albiston AL, Allen AM, et al: The brain renin-angiotensin system: location and physiological roles. Int J Biochem Cell Biol 2003; 35: 901-918. (Pubitemid 36379330)
40. Wright JW, Harding JW: Brain renin-angiotensin -a new look at an old system. Prog Neurobiol 2011; 95: 49-67.
41. Wright JW, Harding JW: The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases. Pflugers Arch 2013; 465: 133-351.
42. Mogi M, Iwanami J, Horiuchi M: Roles of brain angiotensin II in cognitive function and dementia. Int J Hypertens 2012; 2012: 169649.
43. Zhang M, Mao Y, Ramirez SH, Tuma RF, Chabrashvili T: Angiotensin II induced cerebral microvascular inflammation and increased blood-brain barrier permeability via oxidative stress. Neuroscience 2010; 171: 852-858.
44. Li NC, Lee A, Whitmer RA, et al: Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010; 340:b5465.
45. Girouard H, Park L, Anrather J, Zhou P, Iadecola C: Angiotensin II attenuates endothelium-dependent responses in the cerebral microcirculation through nox-2-derived radicals. Arterioscler Thromb Vasc Biol 2006; 26: 826-832. (Pubitemid 43732158)
46. Kehoe PG, Passmore PA: The renin-angiotensin system and antihypertensive drugs in Alzheimer's disease: current standing of the angiotensin hypothesis? J Alzheimer Dis 2012; 30(suppl 2):S251-S268.
47. Jefferson AL: Cardiac output as a potential risk factor for abnormal brain aging. J Alzheimers Dis 2010; 20: 813-821.
48. Vogels RL, Scheltens P, Schroeder-Tanka JM, Weinstein HC: Cognitive impairment in heart failure: a systematic review of the literature. Eur J Heart Fail 2007; 9: 440-449. (Pubitemid 46561483)
49. Sila CA: Cognitive impairment in chronic heart failure. Cleve Clin J Med 2007; 74(suppl 1):S132-S137.
50. Cheng KC, Chen YL, Lai SW, Mou CH, Tsai PY, Sung FC: Patients with chronic kidney disease are at an elevated risk of dementia: a population-based cohort study in Taiwan. BMC Nephrol 2012; 13: 129.
51. Kurella-Tamura M, Wadley V, Yaffe K, et al: Kidney function and cognitive impairment in US adults: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Am J Kidney Dis 2008; 52: 227-234. (Pubitemid 351978145)
52. Fraser CL, Arieff AI: Nervous system complications of uremia. Ann Intern Med 1988; 109: 143-153.
53. Moreira PI, Cardoso SM, Pereira CM, Santos MS, Oliveira CR: Mitochondria as a therapeutic target in Alzheimer's disease and diabetes. CNS Neurol Disord Drug Targets 2009; 8: 492-511.
54. Carvalho C, Cardoso S, Correia SC, et al: Metabolic alterations induced by sucrose intake and Alzheimer's disease promote similar brain mitochondrial abnormalities. Diabetes 2012; 61: 1234-1242.
55. Lue LF, Andrade C, Sabbagh M, Walker D: Is there inflammatory synergy in type 2 diabetes mellitus and Alzheimer's disease. Int J Alzheimers Dis 2012; 2012: 918680.
56. Saijo K, Glass CK: Microglial cell origin and phenotypes in health and disease. Nat Rev Immunol 2011; 11: 775-787.
57. Streit WJ, Xue QS: Alzheimer's disease, neuroprotection, and CNS immunosenescence. Front Pharmacol 2012; 3: 138.
58. Lanctot KL, Rajaram RD, Herrmann N: Therapy for Alzheimer's disease: how effective are current treatments? Ther Adv Neurol Disord 2009; 2: 163-180.
59. Akter K, Lanza EA, Martin SA, Myronyuk N, Rua M, Raffa RB: Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br J Clin Pharmacol 2011; 71: 365-376.
60. Hayden MR, Tyagi SC, Kolb L, Sowers JR, Khanna R: Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis -calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovasc Diabetol 2005; 4: 4.
61. Sowers KM, Hayden MR: Calcific uremic arteriolopathy: pathology, reactive oxygen species and therapeutic approaches. Oxid Med Cell Longev 2010; 3: 109-121.
62. Kappe C, Tracy LM, Patrone C, Iverfeldt K, Sjoholm A: GLP-1 secretion by microglial cells and decreased CNS expression in obesity. J Neuroinflammation 2012; 9: 276.
63. Vrang N, Hansen M, Larsen PJ, Tang-Christensen M: Characterization of brainstem preproglucagon projections to the paraventricular and dorsomedial hypothalamic nuclei. Brain Res 2007; 1149: 118-126. (Pubitemid 46671416)
64. Craft S, Baker LD, Montine TJ, et al: Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012; 69: 29-38.